Applications are now open! The selected KCS recipient will receive an award of $1,000 toward their tuition costs.
Updated statement from Genentech on Hemlibra, March 28, 2018.
The screening kit was developed for broad utility for both laboratories seeking a standardized inhibitor assay for clinical management and multi-center clinical studies of patients with hemophilia A
NHF received information from Genentech’s Clinical Development Lead regarding reports of the death of patients utilizing Hemlibra (emicizumab).
The activity will discuss recent advances in the understanding of inhibitors in patients with hemophilia A, including the risks associated with inhibitors as well as current and new approaches to management.
Aptevo Therapeutics recently announced patient-reported data on individuals currently being treated with IXINITY®, the company’s recombinant factor IX product.
CSL Behring Discontinues Production and Distribution of Monoclate-P®
The study focused on disparities associated with bleeding symptoms, age at diagnosis and provider interventions for females with bleeding disorders.
Runners in the NYC Half Marathon are an inspiration to the bleeding disorders community.
The submission was based on positive results from a multi-stage clinical trial program which included more than 250 children and adults with hemophilia A worldwide
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car